Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could tame high triglycerides

NCT ID NCT07100418

Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental injection called HRS-7249 in 224 adults with hyperlipidemia (high fat levels in the blood). The goal is to see if it safely lowers triglycerides, a type of blood fat linked to heart disease. Participants receive either the drug or a placebo, and researchers track changes in triglyceride levels and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HRS-7249 injection
What this could lead to
If successful, this could lead to a new treatment option for lowering high triglycerides in people with hyperlipidemia, potentially reducing heart disease risk.
What could go wrong
This is an early Phase 2 trial with only 224 participants, so results may not confirm effectiveness or safety. The drug may fail to show benefit or cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

224 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able and willing to provide a written informed consent. 2. Age ≥ 18 years old and \< 80 years old. 3. Male or female. Exclusion Criteria: 1. Acute pancreatitis within 3 months or within 4 weeks or planned for plasma exchange treatment. 2. Malignant tumors within 5 years. 3. Severe cardiovascular or cerebrovascular diseases. 4. Severe trauma or surgery within 6 months or severe infection within 3 months. 5. Previous diagnosed diseases affecting lipid levels. 6. Patients with unstable or severe diseases assessed as at risk by the investigator. 7. Uncontrolled hypertension. 8. Weight loss within 2 months or planned surgery causing unstable weight. 9. Uncontrolled diabetes. 10. Combined hyperthyroidism or hypothyroidism. 11. History of drug or alcohol abuse. 12. Significantly abnormal liver or kidney function. 13. Significantly abnormal blood routine. 14. Significantly abnormal thyroid function. 15. Participated in clinical research within 3 months. 16. Pregnant or lactating women, or refusing contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperlipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperlipidemia

Contacts and locations

Locations

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.